市場調查報告書
商品編碼
1463706
南美洲和中美洲直接面對消費者的基因測試市場預測至 2030 年 - 區域分析 - 按測試類型、技術和配銷通路South & Central America Direct-to-Consumer Genetic Testing Market Forecast to 2030 - Regional Analysis - by Test Type, Technology, and Distribution Channel |
2022年,中南美洲直接面對消費者的基因檢測市場價值為8,964萬美元,預計2030年將達到3.4985億美元;預計2022年至2030年CAGR為18.6%。
單核苷酸多態性 (SNP) 晶片的日益普及推動了南美洲和中美洲直接面對消費者的基因檢測市場
近年來,隨著科學知識的增加,從傳統醫學向個人化醫學的典範穩步轉變。這種轉變歸功於基因工程、單核苷酸多態性 (SNP) 基因分型以及微陣列和生物晶片技術的廣泛採用。具有數十萬個 SNP 的基因微陣列分析平台的引入將鼓勵先進演算法的實施,以更公開地測試個體之間更隱蔽的家譜關係。此外,檢測惡性腫瘤的需求也有所增加。在兒科領域,由於無需將 SNP 變異與大規模缺失雜交,週轉時間短,因此產生了巨大的需求。因此,隨著更多基因異常的檢測和治療,市場預計將會成長。
由於對技術先進和更複雜的 DTC 基因檢測的持續需求,高效、準確的 SNP 晶片的需求不斷增加。人們對 SNP 晶片的高度偏好可歸因於它們能夠測量劑量變化和 DNA 多態性,以及對癌症研究至關重要的各種應用,例如 SNP 微陣列分析。此外,對盡量減少 DTC 基因檢測錯誤的需求日益成長,預計將推動 SNP 技術的採用,為市場成長提供機會。
南美洲和中美洲直接面對消費者的基因檢測市場概述
南美洲和中美洲直接面對消費者的基因檢測市場分為巴西、阿根廷以及南美洲和中美洲其他地區。該地區的市場受到遺傳性疾病發病率迅速上升、老年人口不斷成長、醫療保健系統的發展以及基因檢測意識不斷提高等因素的推動。遺傳疾病以及慢性病盛行率的上升是推動巴西 DTC 基因檢測市場成長的主要因素。例如,遺傳性疾病和先天畸形共同構成巴西嬰兒死亡的第二大常見原因。對個人化醫療的需求不斷成長,疾病診斷新技術的引入,以及行業參與者對開發新診斷技術以提供更快、更準確的結果的關注,預計將成為有利於直接面對消費者的成長的其他值得注意的因素巴西的基因檢測市場。隨著科學家保證追蹤有助於治療肥胖和糖尿病等現代疾病流行的遺傳特徵,巴西的醫學遺傳學領域不斷擴大。此外,巴西私人基因檢測公司(尤其是提供親子鑑定解決方案的公司)的數量正在增加。 2019年,巴西領先的基因檢測實驗室之一GENOMIKA與Veritas簽署協議,將後者與預防醫學和臨床遺傳學相關的全基因組和外顯子組定序服務納入其產品組合。
南美洲和中美洲直接面對消費者的基因檢測市場收入及 2030 年預測(百萬美元)
南美洲和中美洲直接面對消費者的基因檢測市場區隔
南美洲和中美洲直接面對消費者的基因檢測市場分為測試類型、技術、配銷通路和國家。
根據測試類型,南美洲和中美洲直接面對消費者的基因測試市場分為血統測試、預測測試、營養基因組學測試、帶因者測試等。 2022 年,血統測驗細分市場佔據最大佔有率。
從技術面來看,中南美洲直接面對消費者的基因檢測市場分為全基因組定序、單核苷酸多態性晶片、標靶分析等。 2022年,單核苷酸多態性晶片領域佔據最大佔有率。
根據配銷通路,南美洲和中美洲直接面對消費者的基因檢測市場分為線上和線下。 2022 年,線上細分市場佔據了更大的佔有率。
根據國家/地區,南美洲和中美洲直接面對消費者的基因檢測市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,巴西在南美洲和中美洲直接面對消費者的基因檢測市場佔據主導地位。
Ancestry Genomics Inc、Living DNA Ltd、23andMe Inc 和 Genetic Technologies Ltd 是南美洲和中美洲直接面對消費者基因檢測市場的一些領先公司。
表中的內容
The South & Central America direct-to-consumer genetic testing market was valued at US$ 89.64 million in 2022 and is expected to reach US$ 349.85 million by 2030; it is estimated to grow at a CAGR of 18.6% from 2022 to 2030.
Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips Fuels the South & Central America Direct-to-Consumer Genetic Testing Market
There has been a steady paradigm shift from traditional medicine to personalized medicine with increasing scientific knowledge in recent years. This shift is due to advances in genetic engineering, single nucleotide polymorphism (SNP) genotyping, and the high adoption of microarrays and biochip technologies. The introduction of genetic microarray analysis platforms with hundreds of thousands of SNPs will encourage the implementation of advanced algorithms to test for more secluded genealogical relationships more openly between individuals. In addition, the demand for detecting malignant tumors has also increased. In the pediatric field, the short turnaround time without the need to hybridize SNP variations to massive deletions has led to enormous demand. As a result, the market is expected to grow as more genetic abnormalities are detected and treated.
SNP chips with high efficiency and accuracy are witnessing an increase in demand due to the constant need for technologically advanced and more sophisticated DTC genetic testing. A high preference for SNP chips can be attributed to their ability to measure dosage changes and DNA polymorphism, along with various applications such as the SNP microarray analysis that are vital for cancer research. Furthermore, an increasing need to minimize errors in DTC genetic testing is expected to drive the adoption of SNP technology, thereby providing an opportunity for the market growth.
South & Central America Direct-to-Consumer Genetic Testing Market Overview
The South & Central America direct-to-consumer genetic testing market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in this region is driven by factors such as the burgeoning incidences of genetic disorders, the growing geriatric population, developments in healthcare systems, and rising awareness about genetic testing. The rising prevalence of the genetic disease, along with chronic illness, is the primary factor driving the growth of Brazil's DTC genetic testing market. For instance, genetic diseases and congenital abnormalities together represent the second most common cause of mortality among infants in Brazil. The growing demand for personalized medicines, introduction of novel technologies in disease diagnosis, and focus of industry players on developing new diagnostic techniques to provide faster results with high accuracy are expected to be other noteworthy factors to favor the growth of the direct-to-consumer genetic testing market in Brazil. The field of medical genetics has expanded in Brazil as scientists assure to track down genetic traits that will help to treat modern disease epidemics, such as obesity and diabetes. Moreover, the number of private genetic testing companies, particularly offering paternity testing solutions, is on the rise in Brazil. In 2019, GENOMIKA, one of the leading genetic testing laboratories in Brazil, signed an agreement with Veritas to incorporate the latter's Whole Genome and Exome Sequencing services associated with preventive medicine and clinical genetics into its portfolio.
South & Central America Direct-to-Consumer Genetic Testing Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Direct-to-Consumer Genetic Testing Market Segmentation
The South & Central America direct-to-consumer genetic testing market is segmented into test type, technology, distribution channel, and country.
Based on test type, the South & Central America direct-to-consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing market segment held the largest share in 2022.
In terms of technology, the South & Central America direct-to-consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest share in 2022.
Based on distribution channel, the South & Central America direct-to-consumer genetic testing market is bifurcated into online , and offline. The online segment held a larger share in 2022.
Based on country, the South & Central America direct-to-consumer genetic testing market is segmented the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America direct-to-consumer genetic testing market in 2022.
Ancestry Genomics Inc, Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd are some of the leading companies operating in the South & Central America direct-to-consumer genetic testing market.
Table of Content